Literature DB >> 33971749

Telemedicine for management of patients with lung cancer during COVID-19 in an Italian cancer institute: SmartDoc Project.

Alessandro Pardolesi1, Lorenzo Gherzi1, Ugo Pastorino1.   

Abstract

BACKGROUND: Telemedicine, and particularly video-consulting, has rapidly accelerated since the coronavirus disease 2019 (COVID-19) pandemic outbreak. The role of e-healthcare for the management of patients with lung diseases is evolving. We report the results of the initial experience of the SmartDoc Project, a telemedicine program activated in a cancer center (Istituto Nazionale Tumori) at the epicenter of the COVID-19 pandemic onset in Italy.
METHOD: The SmartDoc project was established to guarantee continuity of healthcare services for patients with lung cancer during the COVID-19 pandemic crisis. The project was promoted within the National Health System to create a regulatory framework to authorize and reimburse telemedicine in its care delivery for all patients. At the end of the virtual meeting, patients were asked to answer an online survey.
RESULTS: From June 19 to December 1, 2020, 83 patients participated in the SmartDoc project and received a teleconsultation. The majority of patients were older than 65 years. Among the 83 televisits, 14 (16.9%) were new visits, 2 (2.4%) second opinions, 4 (4.8%) 30-day postsurgery controls, and 63 (75.9%) long-term follow-up visits. A "complete satisfaction" score (5 out of 5 points) was reported in 70.59% of all the respondents; most patients (76.5%) preferred video-consulting and defined it as better than or comparable to an in-person visit.
CONCLUSION: The favorable initial results of this study suggest that telemedicine should continue beyond the pandemic crisis and should be embedded in a more efficient and accessible healthcare system.

Entities:  

Keywords:  Telehealth; lung cancer; telemedicine

Mesh:

Year:  2021        PMID: 33971749     DOI: 10.1177/03008916211012760

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  6 in total

1.  Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement.

Authors:  G D Beretta; R Casolino; D C Corsi; F Perrone; M Di Maio; S Cinieri; G Gobber; M Bellani; F Petrini; M T Zocchi; F Traclò; V Zagonel
Journal:  ESMO Open       Date:  2022-06-23

Review 2.  Telemedicine and virtual respiratory care in the era of COVID-19.

Authors:  Hilary Pinnock; Phyllis Murphie; Ioannis Vogiatzis; Vitalii Poberezhets
Journal:  ERJ Open Res       Date:  2022-07-25

Review 3.  Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies.

Authors:  Louis Fox; Katharina Beyer; Elke Rammant; Esme Morcom; Mieke Van Hemelrijck; Richard Sullivan; Verna Vanderpuye; Dorothy Lombe; Audrey Tieko Tsunoda; Tezer Kutluk; Nirmala Bhoo-Pathy; Shanmugham C Pramesh; Aasim Yusuf; Christopher M Booth; Omar Shamieh; Sabine Siesling; Deborah Mukherji
Journal:  Front Public Health       Date:  2021-11-24

Review 4.  Internet of things in the management of chronic diseases during the COVID-19 pandemic: A systematic review.

Authors:  Ahmadreza Shamsabadi; Zahra Pashaei; Amirali Karimi; Pegah Mirzapour; Kowsar Qaderi; Mahmoud Marhamati; Alireza Barzegary; Amirata Fakhfouri; Esmaeil Mehraeen; SeyedAhmad SeyedAlinaghi; Omid Dadras
Journal:  Health Sci Rep       Date:  2022-03-14

5.  Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician-reported acceptability data from an Australian cancer centre.

Authors:  Anna Collins; Sue-Anne McLachlan; Leeanne Pasanen; Olivia Wawryk; Jennifer Philip
Journal:  Cancer Med       Date:  2022-04-04       Impact factor: 4.711

Review 6.  A Narrative Review of the Launch and the Deployment of Telemedicine in Italy during the COVID-19 Pandemic.

Authors:  Daniele Giansanti; Giovanni Morone; Alice Loreti; Marco Germanotta; Irene Aprile
Journal:  Healthcare (Basel)       Date:  2022-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.